FDA approves Nerlynx to reduce risk of recurrent breast cancer
The U.S. Food and Drug Administration today approved the use of Nerlynx to treat early-stage HER2-positive breast cancer to lower remission risk.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | HER2